AXA IM Prime Impact Master Fund I SCA SICAV-RAIF 13D and 13G filings for Revelation Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 10:19 am Sale |
2023-12-31 | 13G | Revelation Biosciences, Inc. REVB |
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 3,498 0.900% |
-583 (-14.29%) |
Filing |
| 2023-02-14 12:39 pm Purchase |
2022-12-31 | 13G | Revelation Biosciences, Inc. REVB |
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 4,081 8.320% |
4,081 (New Position) |
Filing |